MALAT-1 regulates the AML progression by promoting the m6A modification of ZEB1

Jing Jin; Leihua Fu; Pan Hong; Weiying Feng

doi:10.18388/abp.2020_6017

MALAT-1 regulates the AML progression by promoting the m6A modification of ZEB1

Jing Jin Department of Hematology, Shaoxing People’s Hospital, Shaoxing City, Zhejiang Province, China
Leihua Fu Department of Hematology, Shaoxing People’s Hospital, Shaoxing City, Zhejiang Province, China
Pan Hong Department of Hematology, Shaoxing People’s Hospital, Shaoxing City, Zhejiang Province, China
Weiying Feng Department of Hematology, Shaoxing People’s Hospital, Shaoxing City, Zhejiang Province, China

DOI: https://doi.org/10.18388/abp.2020_6017

Abstract

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) is abnormally upregulated in various human cancers. However, the role of MALAT-1 in acute myeloid leukemia (AML) remains unclear. This study investigated the expression and function of MALAT-1 in AML. MTT assay was used to determine cell viability, qRT-PCR was applied to determine the RNA levels. Western blot was performed to detect the protein expression. Flow cytometry was conducted to measure cell apoptosis. RNA pull-down assay was carried out to detect the interaction between MALAT-1 and METTL14. RNA FISH assay was performed to determine the localization of MALAT-1 and METTL14 in AML cells. Our results have revealed the key role of MEEL14 and m6A modification in AML. Besides, MALAT-1 was significantly up-regulated in AML patients. MALAT-1 knockdown inhibited the proliferation, migration and invasion of AML cells, and induced cell apoptosis; additionally, MALAT-1 binding to METTL14 promoted the m6A modification of ZEB1. Besides, ZEB1 overexpression partially reversed the effect of MALAT-1 knockdown on the cellular functions of AML cells. Taken together, MALAT-1 promoted the aggressiveness of AML through regulating m6A modification of ZEB1.

pdf
html

Published

2023-02-22

Issue

Vol. 70 No. 1 (2023)

Section

Articles

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Acta Biochimica Polonica is an open access quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made, ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. There are no additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.